Beam Therapeutics (NASDAQ:BEAM) Upgraded by Zacks Investment Research to Hold

Beam Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Beam Therapeutics Upgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Beam Therapeutics (NASDAQ:BEAM) Upgraded by Zacks Investment Research to Hold